ABVC BioPharma
ABVC
9 hedge funds and large institutions have $521K invested in ABVC BioPharma in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.79% more ownership
Funds ownership: 0% → 0.79% (+0.79%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$203K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$141K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$115K |
| 4 |
Squarepoint
New York
|
+$54.4K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$42.7K |
Top Sellers
ABVC Hedge Fund Activity: Q3 2021 in Review
9 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in ABVC BioPharma (ABVC) for Q3 2021, worth a combined $521K.
Buyers outnumbered sellers: 9 funds opened new ABVC positions and 0 closed out — a net gain of 9 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $203K.
- 9 institutional investors held ABVC BioPharma (ABVC) as of Q3 2021, up from 0 in Q2 2021.
- Funds reported $521K of ABVC BioPharma stock for Q3 2021.
- 9 funds opened new ABVC BioPharma positions in Q3 2021 and 0 closed out, a net change of +9 holders.
- The largest ABVC BioPharma buyer in Q3 2021 was Sabby Management, an estimated $203K added.
Based on aggregated 13F filings for Q3 2021.